Within the context of breast cancer, we commonly discuss the oncogenic role of amplification of HER2 and its use as an indicator of more aggressive tumor phenotypes that benefits from targeted therapies (i.e., trastuzumab) 34, 35, 36. This evidence concerns the gene ERBB2 and neoplasm.